Related Experiment Videos
VEGF-targeted therapy: therapeutic potential and recent advances
1John Wayne Cancer Institute and St. John's Health Center, Santa Monica, California, USA. lrosen@premiereoncology.com
The Oncologist
|June 22, 2005
Summary
Angiogenesis inhibitors, targeting vascular endothelial growth factor (VEGF), are now viable anticancer therapies. This review details their recent progress in treating breast, lung, and colorectal cancers.
Area of Science:
- Oncology
- Vascular Biology
- Pharmacology
Background:
- Tumor growth necessitates angiogenesis, the formation of new blood vessels.
- Vascular endothelial growth factor (VEGF) and its receptors are critical regulators of angiogenesis.
- Angiogenesis inhibitors represent a promising therapeutic strategy for cancer treatment.
Purpose of the Study:
- To review recent advancements in the clinical application of angiogenesis inhibitors for cancer therapy.
- To highlight the role of VEGF-targeted agents in treating specific cancers.
Main Methods:
- Literature review of recent studies on angiogenesis inhibitors.
- Focus on clinical developments and therapeutic applications.
- Analysis of VEGF-targeted agents in breast, lung, and colorectal cancer treatment.
Main Results:
- Angiogenesis inhibitors have transitioned from theoretical concepts to practical anticancer treatments.
- VEGF-targeted therapies are under extensive investigation for various malignancies.
- Significant progress has been made in applying these inhibitors to breast, lung, and colorectal cancers.
Conclusions:
- Angiogenesis inhibition is a validated approach in oncology.
- VEGF pathway inhibitors offer a targeted strategy for cancer therapy.
- Ongoing research continues to refine the use of these inhibitors in clinical practice.